RxDoctor Payments Data

Xiaowei Xu, MD

Anatomic Pathology · Philadelphia, PANPI 1639115470

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $33,377 of the $34,920 with a category attached, or 95.6%. GSK accounts for 69.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $24,412 and has fallen 64.8% since, to $8,583 in 2025. Among anatomic pathology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$34,920in general payments, 2019–2025

Across 14 payments — averaging $2494.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$24K
  • Merck$9K
  • E.r. Squibb & Sons, L.L.C.$2K
$175,341in research payments, 2019–2025

Across 1 payment — averaging $175,341 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Incyte Corporation$175K

What the payments were for

  • Consulting fees$33,37796%
  • Travel & lodging$1,2694%
  • Food & beverage$2731%

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK2$24,412
Merck11$8,583
E.r. Squibb & Sons, L.L.C.1$1,925

How this compares

$34,920 in reported general payments places this provider in the 95th percentile of 67 anatomic pathology providers in Pennsylvania.

See all anatomic pathology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$37,190
Medicare patients
269
Services billed
878

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other anatomic pathology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →